Barclays boosted its price target for 10x Genomics, which also announced a new research collaboration.
2 reports, 2 independent
Updated Jun 24
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays boosted its price target for 10x Genomics, which also announced a new research collaboration.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
-
10X Genomics
American biotechnology company
Nothing else this week.
Related events
- Financial firms (RBC, Citigroup, Morgan Stanley) issued rating and price target updates for 10X Genomics.
- Barclays raised its price target on Latham Group on September 1, 2026.
- Barclays boosted its price target on Bunge on August 16, 2026.
- Barclays maintained Overweight rating and raised price target on August 29, 2025.
- Barclays raised S&P 500 price targets, noting that both Meta and Amazon are major Big Tech companies and are expected to contribute significantly to capital expenditures (CapEx).